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Introduction
Creatine (Cr) and Phosphocreatine (PCr) constitute an important metabolic energy reservoir system in tissues with fluctuating energy demands, such as skeletal and cardiac muscle. Together with creatine kinases (CKs), Cr and PCr link sites of ATP production within mitochondria to where ATP is consumed, i.e. the contractile machinery and ion pumps such as the Na + /K + ATPase and Ca 2+ ATPases [1] . Myocytes and neurons cannot synthesize Cr, and depend on transport across the cell membrane to maintain Cr at adequate levels within the cell. Cr transport is accomplished by a membrane protein, the creatine transporter (CrT), which belongs to the SLC6 gene family of transporters. Members of this family of proteins include the GABA (GAT1), serotonin (SERT), norepinephrine (NET), and dopamine (DAT) transporters. These closely related Na + /Cl -transporter proteins are regulated by PKC activation that decreases substrate uptake and increases transporter internalization [2] .
Decreases in cardiomyocellular Cr and PCr levels are a well-documented finding in the failing heart and correlate with disease morbidity [3] . In skeletal muscle, Cr and PCr concentrations are altered by acute illness, such as systemic infection [4] . Inborn errors in the gene encoding the CrT protein cause intellectual disabilities, delayed speech development, and behavioral alterations similar to those described in autism [5] .
Oral Cr supplementation is widely used by athletes as a legal ergogenic agent to improve performance. Additionally, there is evidence suggesting that Cr supplementation has beneficial effects in the context of neurodegenerative diseases and a protective effect during ischemic insults to the central nervous system has been reported [6, 7] . Given the role Cr plays in maintaining adequate energy reserves in metabolically active tissues, the reported benefits of oral Cr supplementation, and the observations indicating Cr levels in skeletal and cardiac muscle are affected by disease, it is important to understand how Cr transport is regulated during health and disease.
The molecular mechanisms regulating Cr transport are not well understood. In cardiac and skeletal myocytes Cr uptake is affected by the extracellular concentration of Cr. Increases in extracellular Cr decrease Cr uptake, whereas decreases in Cr content increase Cr transport [8, 9] by changing the V max of transport without significantly altering K m . Recently, we [9] and others [10] have demonstrated that activation of AMPK, the cell's energy master regulator [11] , modulates Cr transport in a tissue specific manner. In cardiomyocytes in culture, AMPK activation increases V max of Cr transport, whereas AMPK activation in kidney cells in culture results in decreases Cr transport. In cardiomyocytes, these changes in V max correlate with decreases in the cell surface fraction of CrT protein, indicating that changes in the cell surface population are associated with the cellular responses to extracellular creatine availability. Experiments in Xenopus laevis oocytes expressing CrT suggest that transport activity may be regulated by SGK1 (serum and glucocorticoid inducible kinase I) in a mechanism involving PIKfyve and the formation of PI(3,5)P 2 [12] . Pharmacological activation of PKC diminishes Cr transport in L6 muscle cells and Xenopus laevis oocytes expressing the CrT protein [8, 13] . PKC isoforms are ubiquitously expressed, but its ε and δ isoforms are prevalent in cardiac muscle. Both isoforms are active during ischemic preconditioning, with PKC having a protective role whereas the δ isoform has a detrimental effect. In chronic heart failure both isoforms are also active and appear to contribute to the development of cardiac hypertrophy [14, 15] and progressive heart failure [16] .
In this study, we tested the hypothesis that changes in the phosphorylation of S and/or T amino acids within the CrT protein sequence underlie the transport modulation observed following PKC activation and changes in Cr availability. We report, for the first time, the results of a systematic study guided by bioinformatics, and designed to identify specific amino acids within the CrT that might influence its response to substrate availability and exposure to PKC. We also determined if other kinases or phosphatases besides PKC could affect Cr transport in cardiomyocytes.
Materials and Methods

cDNA Construction of CrT Mutants
The cDNA encoding the human CrT was a kind gift from Dr. Marc Caron (Duke University, Department of Cell Biology) and was subcloned into pBluescript KS vector (Stratagene, La Jolla, CA). Using polymerase Using the same approach, the natural stop codon was removed and replaced with a unique XbaI site. Two 1kB cassettes encompassing the EcoRI -PstI fragment and the PstI-XbaI fragment were used as templates for site directed mutagenesis. Netphos 2.0, a neural network algorithm [17] was used to predict high probability consensus phosphorylation sites in the primary sequence of CrT protein (P48029). High scoring consensus sites within sequence segments predicted to have an intracellular disposition (selected segments connecting hydrophobic domains and the N-and C-termini, Table 1 ,) were subjected to site directed mutagenesis using the QuickChange mutagenesis system (Agilent, La Jolla, CA). Y residues were replaced with F, whereas S and T amino acids were replaced with A. The EcorI-PstI or PstI-XbaI cassettes bearing the mutant sites were sequenced in their entirety to verify that only the intended nucleotide changes were introduced and swapped into the wild-type background and subcloned in the mammalian expression vector pcDNA 3.1B (Invitrogen, Carlsbad CA). Transfection of this construct results in expression of CrT protein bearing a C-terminal Myc/His tag which does not alter CrT function [9] . As a negative control for expression, the cDNA encoding CrT was subcloned into pcDNA3.1(+) in reverse orientation with respect to the CMV promoter.
Cell Culture, Transfection, and Expression HL-1 cells, an immortalized murine atrial cardiomyocyte cell line [18] , were grown as previously described [9] . GripTite cells (Invitrogen, Carlsbad, CA), a variant of HEK 293 cells, were cultivated following the manufacturer's guidelines. CrT proteins were expressed in HL-1 or Griptite cells following transfection using Lipofectamine 2000 (Life Technologies, Grand Island, NY). Cr-depleted media was prepared as described [9] . The Cr concentration in Cr-depleted media was 0.5-1µM. Cr content in control media was 16.6µM, which closely approximates the Cr concentrations measured in normal mice, rat and human sera [19] . Cr-supplemented media were prepared by adding the appropriate volume of sterile, freshly prepared 30mM Cr solution in water to the Cr-depleted media. This concentration approximates the circulating levels reported in humans (0.5-1mM) receiving Cr supplementation [20] .
Creatine Uptake and phosphorylation modulator assays Cr uptake assays were performed in HL-1 cells expressing the wild type or mutant CrT proteins as previously described (9) . Briefly, 16 hours after transfection the cells were incubated for 48 hours in Cr-depleted or Cr-supplemented media. Assays were performed in triplicate. Protein concentration was determined using a bicinchonic acid (BCA) protein assay (Pierce Biotechnology, Rockford IL) with bovine serum albumin as a standard. In experiments using kinase or phosphatase agonists or inhibitors, HL-1 cell cultures were incubated for 30 minutes at 37°C in media supplemented with either 100µM C2-ceramide, 10 nM Calyculin A, 10 µM Compound C, 100 nM Calphostin, or 100nM β-PMA. All modulators were dissolved in DMSO. Therefore, the control samples were 0.01% v/v DMSO in culture media. Modulators were purchased from EMD Millipore, (Billerica, MA). Unless otherwise indicated, uptake was performed with 15µM Cr uptake buffer and supplemented with Santacruz et 
Response of CrT phosphorylation site mutants to β-PMA and substrate availability
The effects of PKC activation on Cr transport function suggested that the phosphorylation of S and/or T in CrT could modulate changes in Cr uptake in response to β-PME, and, extracellular substrate availability. The NetPhos 2.0 neural network algorithm was used in combination with current topology models to predict intracellular phosphorylation consensus sites with high probability of being modified ( Table 1 ). The consensus sites with the highest probability scores were found clustered at the beginning of the N-terminus (S5 and Y11) and the end of the C-terminus (T620, S623, and S625) of the CrT protein (Table  1) , both predicted to be intracellular. Site-directed mutagenesis was used to replace S or T amino acids with A, and Y with F. These conservative substitutions are not expected to disturb the structure and function of the protein beyond the functional effects attributable to the removal of a phosphate group. To study the possibility that multiple phosphorylation sites were required for the modulation by substrate availability, PKC activation, multisite constructs were also prepared. These constructs eliminated sites with the highest phosphorylation probability scores at C-terminus 4X (T618A, T620A, S623A, S625A), N-terminus 3X (S5A, S12A, S15A) and 6X (S5A, Y11F, T618A, T620A, S623A, S625A), which ablated the highest-probability phosphorylation sites at the N and C-termini. This mutant also included Y11, a non-PKC-dependent phosphorylation candidate, but given its very highpredicted probability for phosphorylation, it was included in the construct.
The initial evaluation of expression and function of the mutant constructs was performed in GripTite cells. All mutant CrT proteins were functional, with transport that exhibited saturation kinetics similar to those observed in the wild-type transporter [9] Table 1 . NetPhos 2.0 neural network algorithm was used in combination with current topology models to predict intracellular phosphorylation consensus sites with high probability of being modified Table 2 . Cr uptake was measured in cultures expressing control, CrT and mutated CrT proteins where one or more consensus phosphorylation site was eliminated by conservative amino acid substitutions as described in experimental procedures. Uptake was measured in control culture media, media depleted of Cr, media supplemented with 1 mM Cr or normal media supplemented with 100 nM β-PMA. 3X, 4X and 6X are multisite mutant CrT proteins where the following amino acids were changed S5A/S12A/S15A, T618A/T620A/S623A/S625A and S5A/Y11F/T618A/T620A/S623A/S625A.Uptake values were normalized to control, and represent the average of a minimum of 3 independent assays, performed each in triplicate ± SEM. All CrT mutants appeared statistically indistinguishable from the wild type CrT (p value was not significant)
Discussion
Cells that cannot synthesize Cr, such as neurons and skeletal or cardiomyocytes, depend on the CrT to maintain the intracellular Cr levels. Abnormalities in Cr transport adversely affect brain function, and decreases in cardiac CrT function contribute to the bioenergetics derangements that characterize the failing myocardium. However, very little is known about the signaling mechanisms responsible for the regulation of Cr uptake. In this study, we first examined the effect of pharmacological manipulation of kinases on CrT function in cardiomyocytes in culture. Consistent with previous studies of L6 myocytes [8] and Xenopus oocytes expressing CrT protein [13] , pharmacologic PKC activation by the phorbolester β-PMA reduced Cr transport V max for Cr transport. This reduction in Cr transport was observed in HL-1 cells grown in all-Cr media concentrations. These observations suggest that S and/or T residues in the CrT protein are the target of phosphorylation by PKC isoform(s). We thus used site directed mutagenesis to eliminate high probability PKC phosphorylation sites individually, or in incremental groups. These mutations did not affect Cr transport, and furthermore, both the individual and multisite CrT mutant proteins responded to PKC activation and substrate availability in a manner equivalent to the wild type CrT.
A reduction in transport has also been reported after PKC activation in other closely related Na + /Cl -transporters, including GAT1, SERT, NET, and DAT. In these transporters, there is an increase in phosphorylation of the transporter proteins that correlates with decreased substrate uptake and increased rates in transporter internalization [2] . In the case of the NET protein, amino acids T258 and S259 are required for the internalization following PKC activation [21, 22] . Netphos 2.0 analysis of NET protein sequence, assigns a moderate phosphorylation probability score to T258 (0.765), whereas S259 has a low score (0.377). The equivalent amino acids in the CrT protein, S256 and T257, have low probability scores (0.253 and 0.339 respectively). Simultaneous elimination of the equivalent residues in the CrT protein (S256A and T257A) on their own (data not shown), or as part of multisite 9X CrT mutant had no effect on the response to PKC activation. A similar result was reported following the elimination of the equivalent sites in the DAT protein, the mutant DAT protein retained wild type responses to PKC activation [23] . Further studies identified the segment encompassed by residues 587-596 at the C-terminus of DAT as a non-classical endocytic signal required for PKC mediated internalization [24] . This sequence is conserved in other transporters of the SLC6 transporter family, but it is not present in CrT.
Ubiquitylation of multiple lysine residues at the N-terminus of DAT is required for internalization of DAT following PKC activation [25, 26] . These lysine residues, although conserved in other neurotransmitter transporters, are also not present in CrT protein. Our results show that Cr transport responds similarly to other members of the SLC6 transporter family to PKC activation (by a reduction in V max ). However, the structural elements mediating the response of CrT may be different from those found in other SLC6 transporters. Although conservative replacement of S and T residues within predicted high-probability phosphorylation consensus sites did not affect the capacity of the CrT to be modulated by PKC activation, the results presented here do not rule out that modulation by PKC rely on CrT's S/T residues that were not analyzed in this study. It may also be possible that a more complicated mode of regulation exists, whereby one or more unidentified residues interact to regulate transport in response to substrate availability and activation/inhibition of S/T kinases.
Modulation by substrate and PKC could require interaction(s) with a presently unidentified intracellular partner protein(s), which could, in turn, be the target(s) of PKC phosphorylation. Changes in the phosphorylation state of these unidentified protein(s) could alter the stability or membrane insertion/retrieval rate for the CrT protein resulting in the observed changes in V max. The presence of different intracellular partners in different tissues could underline the tissue specific differences in Cr transport that are reported in response to AMPK activation in cardiac and renal cells [27] . Given that Cr transport regulation appears to be tissue specific, CrT protein could also be modulated by tissue specific kinases that are not expressed in HL-1 cells. Therefore, residues that do not appear to be necessary for modulation in cardiomyocytes may well be relevant for the modulation of Cr transport in other organs or tissues such as the brain and kidneys. This is the first report of a systematic analysis of potential phosphorylation sites on the CrT protein of any species. Our results, exclude S, T and Y residues with the highest predicted phosphorylation scores as required for the modulation of CrT function by substrate availability and PKC, and suggest that the mechanism(s), and CrT protein structural motifs regulating the responses to substrate availability and PKC activation may be different from those identified in other members of the SLC6 family of membrane proteins.
The identification of residues important in substrate recognition in CrT [28] provides a better understanding of the structural elements involved in the Cr permeation pathway. The reports of high-resolution structures of a prokaryotic homologue of the SLC6 proteins, the LeuT Aa transporter [29] , and more recently of the fruit fly DAT [30] have identified the binding pockets for Cl -and Na + ions required for substrate transport. Additionally, the functional role of post-translational modifications such as glycosylation, intramolecular disulfide bonds, and phosphorylation sites at the C terminus of DAT is also better understood. Whereas, as a member of the SL6A transporter family, CrT shares many basic structural features with these transporters, its functional modulation appears to differ from that of other SLC6 transporters. Elucidation of the structural basis for CrT regulation merits further study because of its importance to the health of certain human tissues.
